Last reviewed · How we verify
NCT06032208
An Extension to Assess the Effect of Expanded Dialysis on Patient Reported Symptoms Using LEVIL
NA trial testing Theranova Dialyzer in End Stage Renal Disease in 100 participants. Currently enrolling.
31 December 2025
Quick facts
| Lead sponsor | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 100 |
| Start date | 1 March 2024 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 2 locations across Canada |
Drugs / interventions tested
- Theranova Dialyzer
Conditions studied
- End Stage Renal Disease — all drugs for End Stage Renal Disease →
Sponsor
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Who can join
18 and older, any sex, with End Stage Renal Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Investigators know that many patients who are on dialysis suffer from burden of unwanted symptoms, which can affect quality of life. The understanding and treatment of symptom burden by healthcare providers is limited and should be recognized as a high priority in the care of the dialysis population. In this study, the investigators will be assessing symptom burden using the London Evaluation of Illness "LEVIL," an application based platform where patients self-report their symptoms with one to three hemodialysis treatments per week for 28 weeks. The investigators would like to compare the currently available dialyzer with a new dialyzer that is capable of removing solutes of higher molecular weight that may or may not cause patients to experience symptoms related to increased amounts of toxins in their blood.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06032208
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Theranova Dialyzer
Trials testing the same drug.
- NCT03640858 — Effect of Expanded Dialysis on Patient Reported Symptoms Using LEVIL · NA · completed
Other recruiting trials for End Stage Renal Disease
Currently open trials in the same condition.
- NCT06257134 — Impact on Quality of Life of Symptoms Routine E-monitoring Among Dialysis Patients. · NA · recruiting
- NCT06310161 — Light Therapy in End Stage Kidney Disease · NA · recruiting
- NCT07360938 — Drug Interaction Potential of Pro-Inflammatory Conditions · recruiting
- NCT06422871 — PReSeRVE-HD: Observational Study of the Merit HeRO® Graft and Super HeRO® in Patients on Hemodialysis · recruiting
- NCT06861816 — Ventilatory Functions and Physical Intolerance in ESRD Adolescents: Response to Program of Walking With Dogs · NA · recruiting
Other London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's trials
Trials by the same sponsor.
- NCT07588711 — Transcutaneous Auricular Vagus Nerve Stimulation as a Treatment for Neuropathic Pain Following Spinal Cord Injury · NA · not yet recruiting
- NCT07585292 — Transcutaneous Auricular Vagus Nerve Stimulation as a Treatment for Musculoskeletal Pain in Cerebral Palsy · NA · not yet recruiting
- NCT07510906 — Evaluation of a Prostate-Targeted PET Imaging System (P-PET) for Detecting Prostate Cancer · NA · not yet recruiting
- NCT03166072 — Health Education vs Meditation in Irreversible Age-Related Vision Loss Patients and Their Caregivers · NA · not yet recruiting
- NCT06035809 — Sensory Motor Arousal Regulation Treatment (SMART) Study · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06032208 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- Last refreshed: 6 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06032208.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing